Journal: bioRxiv
Article Title: Loss of Kmt2c / d promotes gastric cancer initiation and confers vulnerability to mTORC1 inhibition and anti-PD1 immunotherapy
doi: 10.1101/2025.03.27.645747
Figure Lengend Snippet: A, Schematic of mouse models: two doses of tamoxifen (3 mg × 2) were injected intraperitoneally with a 48-hour interval. B, Representative immunofluorescence (IF) staining of EYFP in stomach tissues from Tmprss2-CreER T2 ;Rosa26-LSL-EYFP mice . Nuclei were counterstained with DAPI. Scale bar, 200 µm. C, Kaplan-Meier plots showing the survival of mice after gene knockout. D, Stomach weight of the indicated genetically engineered mouse model (GEMM) six weeks after tamoxifen injection. Data are presented as mean ± SD and analyzed with two-tailed t-test. E, Thickness in corpus mucosa measured by microscopy of hematoxylin and eosin (H&E) staining section. Each dot represents the averaged thickness of 5 random fields from one mouse. Data are presented as mean ± SD and analyzed with two-tailed t-test. F, Representative H&E staining of stomach tissues after tamoxifen administration. Scale bar, 200 µm. G, Pathological staging of stomach cancer progression based on infiltration of tumor cells in TPCD mice. H, Representative H&E staining of small and large intestines in TPCD mice. Scale bar, 1 mm.
Article Snippet: Immunofluorescent staining was performed using primary antibodies against EYFP (2956, Cell Signaling Technology, 1:100), H3K4me1 (5326, Cell Signaling Technology, 1:100), ATP4A (D031-3, MBL Life Science, 1:500), and Puromycin (MABE343, Millipore Sigma, 1:100).
Techniques: Injection, Immunofluorescence, Staining, Gene Knockout, Two Tailed Test, Microscopy